Various promising CAR T-cell-based therapeutic targets have been proposed in preclinical models for CRC, including CEA, EGFR, MUC1, NKG2DL, HER2, and CD133 with many therapeutic strategies [154, 155]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.